Web Analytics

3 Latest Announced Rounds

  • $7,500,000
    Seed

    2 Investors

    Software Development
    Nov 21st, 2024
  • $6,000,000
    Series A

    1 Investors

    Transportation, Logistics, Supply Chain and Storage
    Nov 21st, 2024
  • $30,000,000
    Unknown

    1 Investors

    Financial Services
    Nov 21st, 2024
$1,264.20M Raised in 73 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Judo Bio

start up
United States - Cambridge, MA
  • 08/10/2024
  • Seed
  • $100,000,000

Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.


Related People

Chelsea Place JohnsonCo Founder

Chelsea Place Johnson United States - Greater Boston

N/A